Newer HMG-CoA reductase inhibitor (statin) therapies.
作者信息
Brinton E A
机构信息
University of Arizona College of Medicine, Tucson, USA.
出版信息
Clin Cardiol. 2001;24(7 Suppl):II-10-3. doi: 10.1002/clc.4960240705.
Abstract
Although most patients can achieve their National Cholesterol Education Program goal with a reduction of < or =30% in low-density lipoprotein cholesterol (LDL-C) levels available with all statins, some patients need greater LDL-C lowering. Furthermore, new study data suggest that greater clinical event reduction may be obtained with more aggressive LDL-C lowering and/or with treatment of factors beyond LDL-C. New formulations of statins. including extended-release preparations, are achieving greater reductions in LDL-C levels as well as favorable modification of high-density lipoprotein cholesterol and triglyceride concentrations while maintaining an excellent safety profile.
摘要
相似文献
1
Newer HMG-CoA reductase inhibitor (statin) therapies.
Clin Cardiol. 2001;24(7 Suppl):II-10-3. doi: 10.1002/clc.4960240705.
2
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Am J Med. 2001 Aug 15;111(3):185-91. doi: 10.1016/s0002-9343(01)00799-9.
3
Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Am J Cardiol. 1995 Jul 13;76(2):129A-135A. doi: 10.1016/s0002-9149(05)80035-9.
4
Immediate effect of fluvastatin on lipid levels in acute coronary syndrome.
Mol Cell Biochem. 2007 Dec;306(1-2):19-23. doi: 10.1007/s11010-007-9549-8. Epub 2007 Jul 25.
5
Impact of fluvastatin on hyperlipidemia after renal transplantation.
Transplant Proc. 2004 Sep;36(7):2141-4. doi: 10.1016/j.transproceed.2004.06.027.
6
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
Clin Ther. 2003 Nov;25(11):2738-53. doi: 10.1016/s0149-2918(03)80330-2.
7
Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
Int J Clin Pharmacol Ther. 2007 Jun;45(6):328-34. doi: 10.5414/cpp45328.
8
Managing dyslipidemia in the high-risk patient.
Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. doi: 10.1016/s0002-9149(02)02229-4.
9
Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
Am J Cardiol. 1995 Jul 13;76(2):37A-40A. doi: 10.1016/s0002-9149(05)80014-1.
10
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1.
本文引用的文献
1
Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
Clin Ther. 2001 Feb;23(2):177-92. doi: 10.1016/s0149-2918(01)80001-1.
2
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
JAMA. 2001 Apr 4;285(13):1711-8. doi: 10.1001/jama.285.13.1711.
3
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
Circulation. 2001 Jan 16;103(2):276-83. doi: 10.1161/01.cir.103.2.276.
4
Pleiotropic effects of statins in atherosclerosis and diabetes.
Diabetes Care. 2000 Apr;23 Suppl 2:B72-8.
5
Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.
J Investig Med. 2000 May;48(3):183-9.
6
Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.
Arch Intern Med. 2000 May 8;160(9):1361-9. doi: 10.1001/archinte.160.9.1361.
7
Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.
Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):61-9. doi: 10.1161/01.atv.20.1.61.
8
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.
Circulation. 1999 Jul 20;100(3):230-5. doi: 10.1161/01.cir.100.3.230.
9
Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
Am J Cardiol. 1999 May 15;83(10):1433-6. doi: 10.1016/s0002-9149(99)00120-4.
Zotero 插件